EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have been shown to play a significant role in the treatment of untreated advanced NSCLC, particularly in NSCLC patients with EGFR mutations.